Clinical Trial Update: Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating the use of gemcitabine and docetaxel in recurrent or persistent uterine cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma
• Uterine Corpus Sarcoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2018-10-16